Reporte zur Charge UJ233AA

Symptomtext

the rash was worse; torso very itchy for 1 week; scattered red spots urticaria; Initial information received on 15-Mar-2021 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 80 year old female patient who experienced the rash was worse (rash), torso very itchy for 1 week (pruritus) and scattered red spots urticarial (urticaria), while she received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE]. Medical history included Rash. Medical treatment, vaccination, concomitant medication and family history were not provided. On 18-Oct-2019, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot UJ233AA and expiry date: not reported) via an unknown route at an unknown administration site for prophylactic vaccination. On an unknown date, the patient developed a non-serious the rash was worse (rash), torso very itchy for one week (pruritus) and diagnosis scattered red spots urticaria (urticaria), (unknown latency) following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. It was also reported that the nurse is calling today, because the patient son called the office and asked about the patient (his mom) getting the Covid (coronavirus diseases) Vaccine. During the call, the son of the patient mentioned that his mom had an allergic reaction to the Fluzone Quadrivalent vaccine and questioned if any of the ingredients of the Covid vaccine and the Fluzone Quadrivalent vaccine are the same. Reporter relationship: health care professional (HCP), Product used: Used First time product used: yes still using product: no Was Device Used: yes Details of laboratory data not reported. The patient was treated with BILASTINE (BLEXTEN) (anti-allergy medication). At the time of reporting, the outcome of events was reported as unknown.